출판 : MarketsandMarkets（마켓츠앤마켓츠）출판년월 : 2022년06월
신약 개발 시장의 인공 지능(AI) : 오퍼링(소프트웨어, 서비스), 기술(기계 학습, 딥 러닝), 용도(심장 혈관, 대사, 신경퇴행), 최종 사용자(제약, 생명공학, CRO) – 세계 예측(2022-2027년)
Artificial Intelligence ( AI ) in Drug Discovery Market by Offering (Software, Service), Technology (Machine Learning, Deep Learning), Application (Cardiovascular, Metabolic, Neurodegenerative), End User (Pharma, Biotech,CROs) – Global Forecasts ( 2022 – 2027 )
| 페이지수 | 193 |
| 도표수 | 210 |
| 구성 | 영문조사보고서 |
| 가격 |
The Artificial intelligence/AI in drug discovery Market is projected to reach USD 4.0 billion by 2027 from USD 0.6 billion in 2022, at a CAGR of 45.7% during the forecast period. The growth of this market is primarily driven by factors such as the need to control drug discovery & development costs and reduce the overall time taken in this process, the rising adoption of cloud-based applications and services.
신약 개발 시장의 인공 지능/AI는 예측 기간 동안 45.7%의 CAGR로 2022년 6억 달러에서 2027년 40억 달러에 이를 것으로 예상됩니다. 이 시장의 성장은 주로 약물 발견 및 개발 비용을 제어하고 이 프로세스에 소요되는 전체 시간을 줄여야 할 필요성, 클라우드 기반 애플리케이션 및 서비스의 채택 증가와 같은 요인에 의해 주도됩니다.
On the other hand, the inadequate availability of skilled labor is key factor restraining the market growt at certain extent over the forecast period. .
“Services segment is estimated to hold the major share in 2022 and also expected to grow at the highest over the forecast period”
On the basis of offering, the AI in drug discovery market is bifurcated into software and services. the services segment expected to account for the largest market share of the global AI in drug discovery services market in 2022, and expected to grow fastest CAGR during the forecast period. The advantages and benefits associated with these services and the strong demand for AI services among end users are the key factors for thegrowth of this segment.
“Machine learning technology segment accounted for the largest share of the global AI in drug discovery market”
On the basis of technology, the AI in drug discovery market is segmented into machine learning and other technologies. The machine learning segment accounted for the largest share of the global market in 2021 and expected to grow at the highest CAGR during the forecast period. High adoption of machine learning technology among CRO, pharmaceutical and biotechnology companies and capability of these technologies to extract insights from data sets, which helps accelerate the drug discovery process are some of the factors supporting the market growth of this segment.
“Pharmaceutical & biotechnology companies segment expectd to hold the largest share of the market in 2022”
On the basis of end user, the AI in drug discovery market is divided into pharmaceutical & biotechnology companies, CROs, and research centers and academic & government institutes. In 2021, the pharmaceutical & biotechnology companies segment accounted for the largest share of the AI in drug discovery market. On the other hand, research centers and academic & government institutes are expected to witness the highest CAGR during the forecast period. The strong demand for AI-based tools in making the entire drug discovery process more time and cost-efficient is the key growth factor of pharmaceutical and biotechnology end-user segment.
“North America to dominate the AI in drug discovery market in 2021”
The global AI in the drug discovery market is segmented into four major regions, namely, North America, Europe, APAC, and the Rest of the World. In 2021, North America accounted for the largest and the fastest-growing regional market for AI in drug discovery. North America, which comprises the US, Canada, and Mexico, forms the largest market for AI in drug discovery. These countries have been early adopters of AI technology in drug discovery and development. Presence of key established players, well-established pharmaceutical and biotechnology industry, and high focus on R&D & substantial investment are some of the major factors responsible for the large share and high growth rate of this market.
Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (31%), Tier 2 (28%), and Tier 3 (41%)
• By Designation: C-level (31%), Director-level (25%), and Others (44%)
• By Region: North America (45%), Europe (20%), Asia Pacific (28%), and RoW (7%)
Prominent players in this market are NVIDIA Corporation (US), Microsoft Corporation (US), Google (US), Exscientia (UK), Schrödinger (US), Atomwise, Inc. (US), BenevolentAI (UK), NuMedii (US), BERG LLC (US), Cloud Pharmaceuticals (US), Insilico Medicine (US), Cyclica (Canada), Deep Genomics (Canada), IBM (US), BIOAGE (US), Valo Health (US), Envisagenics (US), twoXAR (US), Owkin, Inc. (US), XtalPi (US), Verge Genomics (US), Biovista (US), Evaxion Biotech (Denmark), Iktos (France), Standigm (South Korea), and BenchSci (Canada). Players adopted organic as well as inorganic growth strategies such as product upgrades, collaborations, agreements, partnerships, and acquisitions to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.
Research Coverage
• The report studies the AI in drug discovery market based on offering, technology, application, end user, and region
• The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth
• The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders
• The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total AI in drug discovery market
• The report forecasts the revenue of market segments with respect to five major regions
Key Benefits of Buying the Report:
The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the AI in drug discovery market and provides them information on key market drivers, restraints, challenges, and opportunities.
목차
TABLE OF CONTENTS
1 INTRODUCTION (Page No. – 26)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY: MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. – 31)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.2 SECONDARY SOURCES
2.2.1 KEY DATA FROM SECONDARY SOURCES
2.3 PRIMARY DATA
2.3.1 PRIMARY SOURCES
2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE, SUPPLY SIDE, DESIGNATION, AND REGION
2.3.2.1 Key industry insights
2.4 MARKET SIZE ESTIMATION
FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 5 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN DRUG DISCOVERY
TABLE 1 FACTOR ANALYSIS
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE AI IN DRUG DISCOVERY MARKET (2022–2027)
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 8 TOP-DOWN APPROACH
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
TABLE 2 MARKET SIZING ASSUMPTIONS
2.6 OVERALL STUDY ASSUMPTIONS
2.7 LIMITATIONS
2.8 RISK ASSESSMENT
TABLE 3 RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET
3 EXECUTIVE SUMMARY (Page No. – 45)
FIGURE 10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2022 VS. 2027 (USD MILLION)
FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET
4 PREMIUM INSIGHTS (Page No. – 48)
4.1 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET OVERVIEW
FIGURE 14 GROWING NEED TO CONTROL DRUG DISCOVERY & DEVELOPMENT COSTS IS A KEY FACTOR DRIVING THE ADOPTION OF AI IN DRUG DISCOVERY SOLUTIONS
4.2 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING (2021–2027)
FIGURE 15 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
4.3 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE & REGION (2021)
FIGURE 16 DEEP LEARNING SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2021
4.4 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 17 NORTH AMERICA IS THE FASTEST-GROWING REGIONAL MARKET FOR AI IN DRUG DISCOVERY
5 MARKET OVERVIEW (Page No. – 52)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 MARKET DRIVERS
5.2.1.1 Growing number of cross-industry collaborations and partnerships
TABLE 4 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2019−2021)
5.2.1.2 Growing need to control drug discovery & development costs and reduce time involved in drug development
5.2.1.3 Patent expiry of several drugs
TABLE 5 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2022
5.2.2 MARKET RESTRAINTS
5.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software
5.2.3 MARKET OPPORTUNITIES
5.2.3.1 Growing biotechnology industry
5.2.3.2 Emerging markets
5.2.3.3 Focus on developing human-aware AI systems
5.2.3.4 Growth in the drugs and biologics market despite the COVID-19 pandemic
5.2.4 MARKET CHALLENGES
5.2.4.1 Limited availability of data sets
5.3 VALUE CHAIN ANALYSIS
FIGURE 19 AI IN DRUG DISCOVERY MARKET: VALUE CHAIN ANALYSIS (2021)
5.4 PORTER’S FIVE FORCES ANALYSIS
TABLE 6 AI IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.5 ECOSYSTEM
FIGURE 20 AI IN DRUG DISCOVERY MARKET ECOSYSTEM
5.6 TECHNOLOGY ANALYSIS
5.7 PRICING ANALYSIS
5.8 BUSINESS MODELS
FIGURE 21 AI IN LIFE SCIENCES: BUSINESS MODELS
FIGURE 22 BENEFITS OF HYBRID BUSINESS MODELS
FIGURE 23 SPECIALIZATION OF AI COMPANIES OVER TIME
5.9 REGULATIONS
5.10 CONFERENCES AND WEBINARS
5.11 CASE STUDY ANALYSIS
5.11.1 CASE STUDY 1
5.11.2 CASE STUDY 2
6 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING (Page No. – 66)
6.1 INTRODUCTION
TABLE 7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
6.2 SOFTWARE
6.2.1 BENEFITS OFFERED BY SOFTWARE IN DRUG DISCOVERY & STRONG DEMAND AMONG END USERS ARE DRIVING SEGMENT GROWTH
TABLE 8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY REGION, 2020–2027 (USD MILLION)
TABLE 9 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 10 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 11 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 SERVICES
6.3.1 SERVICES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
TABLE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY REGION, 2020–2027 (USD MILLION)
TABLE 13 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 14 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 15 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2020–2027 (USD MILLION)
7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY (Page No. – 72)
7.1 INTRODUCTION
TABLE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
7.2 MACHINE LEARNING
TABLE 17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2020–2027 (USD MILLION)
TABLE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY REGION, 2020–2027 (USD MILLION)
TABLE 19 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 20 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 21 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.1 DEEP LEARNING
7.2.1.1 Deep learning accelerates the discovery process of life-saving drugs and precision medicine
TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY REGION, 2020–2027 (USD MILLION)
TABLE 23 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 24 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 25 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.2 SUPERVISED LEARNING
7.2.2.1 Supervised learning can be applied in drug repositioning
TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY REGION, 2020–2027 (USD MILLION)
TABLE 27 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 28 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 29 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.3 REINFORCEMENT LEARNING
7.2.3.1 Insilico Medicine is a pioneer in the application of reinforcement learning in drug discovery
TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2020–2027 (USD MILLION)
TABLE 31 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 32 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 33 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.4 UNSUPERVISED LEARNING
7.2.4.1 Unsupervised learning can be more unpredictable than alternate models
TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2020–2027 (USD MILLION)
TABLE 35 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 36 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 37 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2020–2027 (USD MILLION)
7.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 39 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 40 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 41 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 OTHER TECHNOLOGIES
TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 43 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 44 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 45 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2027 (USD MILLION)
8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION (Page No. – 87)
8.1 INTRODUCTION
TABLE 46 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2 IMMUNO-ONCOLOGY
8.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE SEGMENT GROWTH
TABLE 47 INDICATIVE LIST OF INITIATIVES IN IMMUNO-ONCOLOGY DRUG DEVELOPMENT
TABLE 48 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY REGION, 2020–2027 (USD MILLION)
TABLE 49 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 50 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 51 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 NEURODEGENERATIVE DISEASES
8.3.1 AI IS BEING USED TO RESOLVE EXISTING CHALLENGES IN NEUROLOGICAL DISEASE DRUG DEVELOPMENT
TABLE 52 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 53 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 54 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 55 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEURODEGENERATIVE DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
8.4 CARDIOVASCULAR DISEASES
8.4.1 RISING DEMAND FOR CVD DRUGS IS DRIVING SEGMENT GROWTH
TABLE 56 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT
TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 58 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 59 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 60 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
8.5 METABOLIC DISEASES
8.5.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES IS DRIVING ITS ADOPTION IN THIS SEGMENT
TABLE 61 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 62 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 63 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 64 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2020–2027 (USD MILLION)
8.6 OTHER APPLICATIONS
TABLE 65 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 66 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 67 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 68 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER (Page No. – 98)
9.1 INTRODUCTION
TABLE 69 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT HAS DRAWN END-USER ATTENTION TO AI
TABLE 70 INDICATIVE LIST OF DEVELOPMENTS RELATED TO THE USE OF AI IN THE PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY
TABLE 71 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 72 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 73 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 74 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
9.3 CONTRACT RESEARCH ORGANIZATIONS
9.3.1 GROWING TREND OF OUTSOURCING TO PROVIDE SIGNIFICANT OPPORTUNITIES FOR CONTRACT RESEARCH ORGANIZATIONS
TABLE 75 INDICATIVE LIST OF COLLABORATIONS WITH CROS
TABLE 76 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 77 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 78 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 79 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
9.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
9.4.1 THIS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
TABLE 80 INDICATIVE LIST OF RESEARCH COLLABORATIONS
TABLE 81 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
TABLE 82 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 83 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 84 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION)
10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION (Page No. – 106)
10.1 INTRODUCTION
TABLE 85 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 24 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT
TABLE 86 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 87 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 88 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 89 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 90 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.1.1 Strong economy and trend of early adoption of technologies are driving market growth in the US
TABLE 91 INDICATIVE LIST OF STRATEGIC DEVELOPMENTS IN THE US MARKET
TABLE 92 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 93 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 94 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 95 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Growing research on AI technologies and emergence of new AI-based start-ups will support market growth in Canada
TABLE 96 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 97 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 98 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 99 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.3 MEXICO
10.2.3.1 Government initiatives to support market growth in Mexico
TABLE 100 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 101 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 102 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 103 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3 EUROPE
FIGURE 25 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT
TABLE 104 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 105 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 106 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 107 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 108 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.1 UK
10.3.1.1 UK holds the largest share of the European market
TABLE 109 INDICATIVE LIST OF STRATEGIC DEVELOPMENTS IN THE UK
TABLE 110 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 111 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 112 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 113 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Government support and favorable training programs are key market drivers in Germany
TABLE 114 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 115 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 116 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 117 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Strong government support and favorable strategies & initiatives to drive market growth in France
TABLE 118 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 119 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 120 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 121 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Presence of a strong pharmaceutical industry in Italy to drive market growth
TABLE 122 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 123 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 124 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 125 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.5 REST OF EUROPE
TABLE 126 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 127 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 128 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 129 ROE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
TABLE 130 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 131 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 132 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 133 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 134 APAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Japan dominates the APAC market for AI in drug discovery
TABLE 135 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 136 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 137 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 138 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Growing CMO market and cross-industry collaborations are factors responsible for market growth in China
TABLE 139 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 140 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 141 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 142 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Steady adoption of AI technologies will drive market growth in India
TABLE 143 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 144 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 145 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 146 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 147 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 148 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 149 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 150 ROAPAC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 151 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2020–2027 (USD MILLION)
TABLE 152 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 153 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 154 ROW: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. – 140)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE AI IN DRUG DISCOVERY MARKET
11.3 MARKET RANKING ANALYSIS
TABLE 155 AI IN DRUG DISCOVERY MARKET RANKING ANALYSIS, BY KEY PLAYER, 2021
11.4 COMPETITIVE BENCHMARKING
TABLE 156 AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 157 AI IN DRUG DISCOVERY MARKET: APPLICATION FOOTPRINT OF KEY PLAYERS
TABLE 158 AI IN DRUG DISCOVERY MARKET: REGIONAL FOOTPRINT OF KEY PLAYERS
11.5 COMPETITIVE LEADERSHIP MAPPING
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 26 AI IN DRUG DISCOVERY MARKET: GLOBAL COMPANY EVALUATION MATRIX, 2021
11.6 COMPETITIVE LEADERSHIP MAPPING – START-UPS/SMES
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 27 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
11.7 COMPETITIVE SITUATIONS AND TRENDS
TABLE 159 PRODUCT LAUNCHES
TABLE 160 DEALS
12 COMPANY PROFILES (Page No. – 151)
(Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) *
12.1 KEY PLAYERS
12.1.1 MICROSOFT
TABLE 161 MICROSOFT: BUSINESS OVERVIEW
FIGURE 28 MICROSOFT: COMPANY SNAPSHOT (2020)
TABLE 162 MICROSOFT: DEALS
12.1.2 NVIDIA
TABLE 163 NVIDIA: BUSINESS OVERVIEW
FIGURE 29 NVIDIA: COMPANY SNAPSHOT (2022)
TABLE 164 NVIDIA: EXPANSIONS
TABLE 165 NVIDIA: DEALS
12.1.3 EXSCIENTIA
TABLE 166 EXSCIENTIA: BUSINESS OVERVIEW
FIGURE 30 EXSCIENTIA: COMPANY SNAPSHOT (2021)
12.1.4 GOOGLE
TABLE 167 GOOGLE: BUSINESS OVERVIEW
FIGURE 31 GOOGLE: COMPANY SNAPSHOT (2021)
12.1.5 BENEVOLENTAI
TABLE 168 BENEVOLENTAI: BUSINESS OVERVIEW
12.1.6 NUMEDII, INC.
TABLE 169 NUMEDII: BUSINESS OVERVIEW
12.1.7 BERG, LLC
TABLE 170 BERG, LLC: BUSINESS OVERVIEW
12.1.8 ATOMWISE
TABLE 171 ATOMWISE: BUSINESS OVERVIEW
12.1.9 DEEP GENOMICS
TABLE 172 DEEP GENOMICS: BUSINESS OVERVIEW
12.1.10 INSILICO MEDICINE
TABLE 173 INSILICO MEDICINE: BUSINESS OVERVIEW
12.1.11 SCHRÖDINGER, INC.
TABLE 174 SCHRÖDINGER: BUSINESS OVERVIEW
FIGURE 32 SCHRÖDINGER: COMPANY SNAPSHOT (2021)
12.1.12 IBM
TABLE 175 IBM: BUSINESS OVERVIEW
FIGURE 33 IBM: COMPANY SNAPSHOT (2022)
TABLE 176 IBM: DEALS
TABLE 177 IBM: OTHER DEVELOPMENTS
12.2 OTHER PLAYERS
12.2.1 CYCLICA INC.
12.2.2 CLOUD PHARMACEUTICALS
12.2.3 BIOAGE
12.2.4 ENVISAGENICS
12.2.5 TWOXAR, INC. (ARIA PHARMACEUTICALS)
12.2.6 OWKIN, INC.
12.2.7 XTALPI, INC.
12.2.8 VERGE GENOMICS
12.2.9 IKTOS
12.2.10 EVAXION BIOTECH
12.2.11 STANDIGM
12.2.12 VALO HEALTH
12.2.13 BIOVISTA
12.2.14 BENCHSCI
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
13 APPENDIX (Page No. – 192)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
